Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Assessment of biochemical recurrence of prostate cancer (Review).

Lin X, Kapoor A, Gu Y, Chow MJ, Xu H, Major P, Tang D.

Int J Oncol. 2019 Dec;55(6):1194-1212. doi: 10.3892/ijo.2019.4893. Epub 2019 Oct 4.

2.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.

Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE.

Eur Urol Oncol. 2018 Sep;1(4):276-282. doi: 10.1016/j.euo.2018.04.014. Epub 2018 Sep 28.

PMID:
31100248
3.

Markers and meaning of primary treatment failure.

Swindle PW, Kattan MW, Scardino PT.

Urol Clin North Am. 2003 May;30(2):377-401. Review.

PMID:
12735513
4.

Genomic Predictors of Outcome in Prostate Cancer.

Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR.

Eur Urol. 2015 Dec;68(6):1033-44. doi: 10.1016/j.eururo.2015.04.008. Epub 2015 Apr 23. Review.

5.
6.

Transcriptome analysis reveals a long non-coding RNA signature to improve biochemical recurrence prediction in prostate cancer.

Xu J, Lan Y, Yu F, Zhu S, Ran J, Zhu J, Zhang H, Li L, Cheng S, Xiao Y, Li X.

Oncotarget. 2018 May 18;9(38):24936-24949. doi: 10.18632/oncotarget.25048. eCollection 2018 May 18.

7.

Diagnostic associations of gene expression signatures in prostate cancer tissue.

Nguyen HG, Welty CJ, Cooperberg MR.

Curr Opin Urol. 2015 Jan;25(1):65-70. doi: 10.1097/MOU.0000000000000131. Review.

8.

Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.

Noh BJ, Sung JY, Kim YW, Chang SG, Park YK.

Oncol Lett. 2016 Jun;11(6):3621-3630. Epub 2016 Apr 19.

9.

Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Review.

PMID:
29129398
10.

PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.

Jiang Q, Xie M, He M, Yan F, Chen M, Xu S, Zhang X, Shen P.

Medicine (Baltimore). 2019 Jan;98(1):e13820. doi: 10.1097/MD.0000000000013820.

11.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559
12.

Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.

Jiang Y, Mei W, Gu Y, Lin X, He L, Zeng H, Wei F, Wan X, Yang H, Major P, Tang D.

Mol Oncol. 2018 Sep;12(9):1559-1578. doi: 10.1002/1878-0261.12359. Epub 2018 Aug 11.

13.

A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.

Huang TB, Dong CP, Zhou GC, Lu SM, Luan Y, Gu X, Liu L, Ding XF.

Int Urol Nephrol. 2017 May;49(5):825-835. doi: 10.1007/s11255-017-1536-8. Epub 2017 Feb 10.

PMID:
28188414
14.

Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports.

Xie H, Xie B, Liu C, Wang J, Xu Y.

Onco Targets Ther. 2017 Oct 24;10:5089-5097. doi: 10.2147/OTT.S132653. eCollection 2017.

15.

Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.

Budäus L, Isbarn H, Tennstedt P, Salomon G, Schlomm T, Steuber T, Haese A, Chun F, Fisch M, Michl U, Heinzer H, Huland H, Graefen M.

BJU Int. 2012 Dec;110(11):1714-20. doi: 10.1111/j.1464-410X.2012.11147.x. Epub 2012 Apr 23.

16.

Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.

Hamada R, Nakashima J, Ohori M, Ohno Y, Komori O, Yoshioka K, Tachibana M.

Int J Clin Oncol. 2016 Jun;21(3):595-600. doi: 10.1007/s10147-015-0923-3. Epub 2015 Nov 19. Erratum in: Int J Clin Oncol. 2016 Jun;21(3):601.

PMID:
26585896
17.

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy.

Lee RJ, Tzou KS, Heckman MG, Hobbs CJ, Rawal B, Diehl NN, Peterson JL, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Wong W, Schild S, Pisansky TM, Buskirk SJ.

BJU Int. 2016 Aug;118(2):236-42. doi: 10.1111/bju.13229. Epub 2015 Aug 22.

18.

Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.

Wang X, Yang J, Guo G, Feng R, Chen K, Liao Y, Zhang L, Sun L, Huang S, Chen JL.

Mol Cancer. 2019 Apr 8;18(1):84. doi: 10.1186/s12943-019-1013-3.

19.

Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.

Eur Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.

PMID:
24345725
20.

Optimising preoperative risk stratification tools for prostate cancer using mpMRI.

Reisæter LAR, Fütterer JJ, Losnegård A, Nygård Y, Monssen J, Gravdal K, Halvorsen OJ, Akslen LA, Biermann M, Haukaas S, Rørvik J, Beisland C.

Eur Radiol. 2018 Mar;28(3):1016-1026. doi: 10.1007/s00330-017-5031-5. Epub 2017 Oct 6.

Supplemental Content

Support Center